» Articles » PMID: 17363730

Regulation of Toll-like Receptor-mediated Inflammatory Response by Complement in Vivo

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2007 Mar 17
PMID 17363730
Citations 175
Authors
Affiliations
Soon will be listed here.
Abstract

Toll-like receptors (TLRs) and complement are 2 components of innate immunity that are critical for first-line host defense and elicitation of adaptive immune responses. Many pathogen-associated molecular patterns activate both TLR and complement, but whether and how these 2 systems, when coactivated in vivo, interact with each other has not been well studied. We demonstrate here a widespread regulation of TLR signaling by complement in vivo. The TLR ligands lipopolysacharride (TLR4), zymosan (TLR2/6), and CpG oligonucleotide (TLR9) caused, in a complement-dependent manner, strikingly elevated plasma interleukin-6 (IL-6), tumor necrosis factor alpha (TNF-alpha), and IL-1beta, and/or decreased plasma IL-12 levels in mice deficient in the membrane complement inhibitor decay-accelerating factor (DAF). A similar outcome was observed in wild-type mice cotreated with the TLR ligands and cobra venom factor, a potent complement activator. The regulatory effect of complement on TLR-induced cytokine production in vivo was mediated by the anaphylatoxin receptors C5aR and C3aR. Additionally, changes in lipopolysaccharide (LPS)-induced cytokine production in DAF-deficient mice correlated with increased mitogen-activated protein kinase and nuclear factor-kappaB activation in the spleen. These results reveal a strong interaction between complement and TLR signaling in vivo and suggest a novel mechanism by which complement promotes inflammation and modulates adaptive immunity.

Citing Articles

Neuroinflammation in Alzheimer disease.

Heneka M, van der Flier W, Jessen F, Hoozemanns J, Thal D, Boche D Nat Rev Immunol. 2024; .

PMID: 39653749 DOI: 10.1038/s41577-024-01104-7.


Immunity and Coagulation in COVID-19.

Avdonin P, Blinova M, Serkova A, Komleva L, Avdonin P Int J Mol Sci. 2024; 25(20).

PMID: 39457048 PMC: 11508857. DOI: 10.3390/ijms252011267.


Toll-like receptors and integrins crosstalk.

Alhamdan F, Bayarsaikhan G, Yuki K Front Immunol. 2024; 15:1403764.

PMID: 38915411 PMC: 11194410. DOI: 10.3389/fimmu.2024.1403764.


Role of Complement Components in Asthma: A Systematic Review.

Tornyi I, Horvath I J Clin Med. 2024; 13(11).

PMID: 38892755 PMC: 11172655. DOI: 10.3390/jcm13113044.


Bacteria-derived extracellular vesicles: endogenous roles, therapeutic potentials and their biomimetics for the treatment and prevention of sepsis.

Effah C, Ding X, Drokow E, Li X, Tong R, Sun T Front Immunol. 2024; 15:1296061.

PMID: 38420121 PMC: 10899385. DOI: 10.3389/fimmu.2024.1296061.


References
1.
Spicer A, Seldin M, Gendler S . Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. J Immunol. 1995; 155(6):3079-91. View

2.
Buhl A, Osawa S, Johnson G . Mitogen-activated protein kinase activation requires two signal inputs from the human anaphylatoxin C5a receptor. J Biol Chem. 1995; 270(34):19828-32. DOI: 10.1074/jbc.270.34.19828. View

3.
Song W, Deng C, Raszmann K, MOORE R, Newbold R, McLachlan J . Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol. 1996; 157(9):4166-72. View

4.
Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, Sakagami M . Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity. 1998; 9(1):143-50. DOI: 10.1016/s1074-7613(00)80596-8. View

5.
Short A, Wong A, Finch A, Haaima G, Shiels I, Fairlie D . Effects of a new C5a receptor antagonist on C5a- and endotoxin-induced neutropenia in the rat. Br J Pharmacol. 1999; 126(3):551-4. PMC: 1565845. DOI: 10.1038/sj.bjp.0702338. View